Compugen's (CGEN) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Compugen's stock has been given a "sell (D-)" rating by Weiss Ratings, indicating ongoing investor caution.
• The company reported disappointing earnings, posting a loss of ($0.08) EPS, falling short of analysts' expectations of ($0.07).
• Institutional investors are actively engaging with Compugen, with noteworthy increases in holdings by firms like Jane Street Group LLC, which raised its stake by 1,077% recently.

Compugen (NASDAQ:CGEN - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut Compugen from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $4.00.

Compugen Price Performance

CGEN stock traded up $0.05 during midday trading on Wednesday, hitting $1.81. The stock had a trading volume of 405,295 shares, compared to its average volume of 382,638. The firm has a market cap of $161.52 million, a price-to-earnings ratio of -8.23 and a beta of 2.61. The business has a 50-day moving average of $1.47 and a two-hundred day moving average of $1.50. Compugen has a 52-week low of $1.13 and a 52-week high of $2.66.

Compugen (NASDAQ:CGEN - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Compugen had a negative return on equity of 34.77% and a negative net margin of 87.45%.The company had revenue of $1.26 million during the quarter, compared to analysts' expectations of $3.95 million. Research analysts predict that Compugen will post -0.03 earnings per share for the current year.

Institutional Trading of Compugen

A number of hedge funds and other institutional investors have recently bought and sold shares of CGEN. US Bancorp DE purchased a new stake in shares of Compugen during the first quarter worth about $29,000. ARK Investment Management LLC purchased a new stake in shares of Compugen during the first quarter worth about $1,323,000. Calamos Wealth Management LLC purchased a new stake in shares of Compugen during the first quarter worth about $43,000. Schnieders Capital Management LLC purchased a new stake in shares of Compugen during the first quarter worth about $131,000. Finally, Jane Street Group LLC grew its position in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company's stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.